Saniona AB
STO:SANION
Intrinsic Value
Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. [ Read More ]
The intrinsic value of one SANION stock under the Base Case scenario is 2.331 SEK. Compared to the current market price of 1.798 SEK, Saniona AB is Undervalued by 23%.
Valuation Backtest
Saniona AB
Run backtest to discover the historical profit from buying and selling SANION stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Saniona AB
Current Assets | 45.2m |
Cash & Short-Term Investments | 31m |
Receivables | 10.7m |
Other Current Assets | 3.5m |
Non-Current Assets | 19m |
Long-Term Investments | 3.5m |
PP&E | 10.5m |
Intangibles | 4.9m |
Current Liabilities | 17.7m |
Accounts Payable | 8.2m |
Other Current Liabilities | 9.5m |
Non-Current Liabilities | 68.4m |
Long-Term Debt | 65.9m |
Other Non-Current Liabilities | 2.5m |
Earnings Waterfall
Saniona AB
Revenue
|
16.8m
SEK
|
Cost of Revenue
|
-52.7m
SEK
|
Gross Profit
|
-35.9m
SEK
|
Operating Expenses
|
-43.5m
SEK
|
Operating Income
|
-79.3m
SEK
|
Other Expenses
|
-16.5m
SEK
|
Net Income
|
-95.8m
SEK
|
Free Cash Flow Analysis
Saniona AB
SANION Profitability Score
Profitability Due Diligence
Saniona AB's profitability score is 14/100. The higher the profitability score, the more profitable the company is.
Score
Saniona AB's profitability score is 14/100. The higher the profitability score, the more profitable the company is.
SANION Solvency Score
Solvency Due Diligence
Saniona AB's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Saniona AB's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SANION Price Targets Summary
Saniona AB
According to Wall Street analysts, the average 1-year price target for SANION is 6.12 SEK with a low forecast of 6.06 SEK and a high forecast of 6.3 SEK.
Shareholder Return
SANION Price
Saniona AB
Average Annual Return | -32.91% |
Standard Deviation of Annual Returns | 33.56% |
Max Drawdown | -96% |
Market Capitalization | 200m SEK |
Shares Outstanding | 111 238 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. The company operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The firm develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The firm is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Officers
The intrinsic value of one SANION stock under the Base Case scenario is 2.331 SEK.
Compared to the current market price of 1.798 SEK, Saniona AB is Undervalued by 23%.